Drugs / Xcell Amnio Matrix
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07116174 | Aug 2025 → Aug 2026 overdue | ulcer of lower limbs | New Horizon Medical Solutions | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xcell Amnio Matrix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07116174 ↗ |
| Known as | XAM | “The goal of this clinical trial is to evaluate the clinical outcomes of Diabetic Foot Ulcers (DFUs) treated with a weekly application of Xcell Amnio MatrixTM (XAM) as adjunct...” NCT07116174 ↗ |